---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034710"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:16:37.419099+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports FY2023 net loss $117.5M; deprioritizes NKX101, advances NKX019 in autoimmune

## Summary
- FY2023 net loss of $117.5M ($2.40 per basic/diluted share).
- Year-end cash, equivalents & investments $250.9M; expected to fund operations into 2026.
- NKX019 lupus nephritis trial on track to dose first patient in H1 2024.
- NKX101 AML program deprioritized after CR/CRi rate 5/20 vs 4/6 in first 6 patients.
- NKX019 compressed dosing cohort in NHL; preliminary data expected mid-2024.

## SEC filing metadata
- accession: 0000950170-24-034710
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/0000950170-24-034710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/nktx-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034710
- JSON: https://secwatch.observer/filing/0000950170-24-034710.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034710.txt

## Key facts
- Earnings Releases
  Nkarta, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/0000950170-24-034710-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.